AcouSort (ACOU) Q3 2025 earnings summary

Executive summary

• Expanded collaborations in diagnostics and cell therapy, including new orders and technology evaluation agreements with European and Danish partners.

• Showcased technology at major industry events, including the 10th Bioproduction Congress in Lyon.

• NIH publication highlighted AcouWash technology's role in automating radiolabelling workflows.

Financial highlights

• Q3 2025 net sales: TSEK 1,248 (up from 1,198 year-over-year); nine-month net sales: TSEK 4,394 (up from 3,516 year-over-year).

• Q3 2025 result before tax: TSEK -2,692 (improved from -3,807 year-over-year); nine-month result before tax: TSEK -9,523 (improved from -12,249 year-over-year).

• Result per share Q3: SEK -0.12 (vs. -0.25); nine months: SEK -0.53 (vs. -0.82).

• Cash and cash equivalents at period end: TSEK 11,828 (vs. 9,538 prior year).

Outlook and guidance

• Focus remains on strengthening positions in diagnostics, cell therapy, flow cytometry, and quality control through ongoing and new partnerships.

• Stable financial position supports continued development and commercialization efforts.